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Abstract
Introduction Although breast carcinoma (BC) is the most
common malignancy affecting Jordanian females and the
affected population in Jordan is younger than that in the West,
no information is available on its biological characteristics. Our
aims in this study are to evaluate the expression of estrogen
receptor (ER) and progesterone receptor (PR) and Her-2/neu
overexpression in BC in Jordan, and to compare the expression
of these with other prognostic parameters for BC such as
histological type, histological grade, tumor size, patients' age,
and number of lymph node metastases.
Method This is a retrospective study conducted in the
Department of Pathology at Jordan University of Science and
Technology. A confirmed 91 cases of BC diagnosed in the
period 1995 to 1998 were reviewed and graded. We used
immunohistochemistry to evaluate the expression of ER, PR, and
Her-2. Immunohistochemical findings were correlated with age,
tumor size, grade and axillary lymph node status.
Results Her-2 was overexpressed in 24% of the cases. The
mean age of Her-2 positive cases was 42 years as opposed to
53 years among Her-2 negative cases (p = 0.0001). Her-2
expression was inversely related to ER and PR expression. Her-
2 positive tumors tended to be larger than Her-2 negative
tumors with 35% overexpression among T3 tumors as opposed
to 22% among T2 tumors (p = 0.13). Her-2 positive cases
tended to have higher rates of axillary metastases, but this did
not reach statistical significance. ER and PR positive cases
were seen in older patients with smaller tumor sizes.
Conclusion Her-2 overexpression was seen in 24% of BC
affecting Jordanian females. Her-2 overexpression was
associated with young age at presentation, larger tumor size,
and was inversely related to ER and PR expression. One-fifth of
the carcinomas were Her-2 positive and ER negative. This group
appears to represent an aggressive form of BC presenting at a
young age with large primary tumors and a high rate of four or
more axillary lymph node metastases.
Introduction
According to data from the Jordan National Cancer Registry
[1], breast carcinoma is the most common malignant neo-
plasm affecting Jordanian females. Others as well as our own
group have shown that females with breast carcinoma in Jor-
dan are significantly younger than those in the West, with an
average age ranging from 44.5 to 47 years [2-5]. Such data
may reflect the fact that the population of Jordan is, on aver-
age, younger than in the West, but it may also suggest that
breast carcinoma in Jordan has some unique biological fea-
tures that need to be explored. Estrogen receptor (ER), pro-
gesterone receptor (PR) and human epidermal growth factor
receptor 2 (Her-2) expression are crucially important in the
biology of breast carcinoma, and yet the expression of these
have not been studied in breast carcinoma in Jordan. It is
known that ER and PR expression are the only predictive fac-
tors with proven usefulness in selecting patients who are likely
to respond to adjuvant endocrine therapy [6,7]. Patients lack-
ing these receptors tend to have shorter disease free survival
and earlier recurrences than those expressing these receptors
[6]. Her-2, otherwise known as neu or c-erbB-2, is the product
of an oncogene amplified and overexpressed in 20% to 30%
of breast carcinomas [8-13]. In most studies, overexpression
of Her-2 is associated with adverse prognosis independent of
other prognostic factors, even when multivariate analysis was
used for the outcome analysis [14]. The prognostic effects of
Her-2 expression appear to be stronger in node positive carci-
nomas than in node negative carcinomas [15]. Although Her-
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2 expression in breast carcinomas is associated with resist-
ance to regimens using cyclophosphamide and methotrexate
[16], it is associated with better response to regimens using
doxorubicin [17]. Her-2 has gained an even greater deal of
attention lately after the introduction of a humanized mono-
clonal antibody known as trastuzumab that can be effective in
the treatment of cases in which this oncogene product is over-
expressed [18-23].
Our aims in this study are to evaluate the expression of ER and
PR and the overexpression of Her-2/neu in patients with
breast cancer in Jordan, and to compare the expression of
these with other prognostic parameters for mammary carcino-
mas, such as histological type, histological grade, tumor size,
patients' age and number of lymph node metastases.
Materials and methods
This is a retrospective study of breast carcinoma cases diag-
nosed in the period January 1995 to December 1998 at the
Department of Pathology, Jordan University of Science and
Technology (JUST) in Irbid, Jordan. The Department of Pathol-
ogy at JUST is the sole provider of histopathology services in
the north of Jordan. Only cases among Jordanian females with
adequate tissue to perform immunhistochemical examination
were included. Of 135 cases of breast carcinomas diagnosed
in this period, 91 (67%) fulfilled these criteria. The cases
reflect the overall distribution of all breast carcinomas diag-
nosed in the same period of time.
Sections from the cases were reviewed by one of us (NMA),
and the tumors were typed according to the WHO classifica-
tion system [24]. For invasive ductal carcinomas, the Notting-
ham combined histologic system was used for grading [25].
Grade 1 carcinoma includes tumors with combined scores of
3, 4 or 5; grade 2 includes scores of 6 and 7; and grade 3
includes tumors with the scores of 8 and 9.
Sections were cut at 4 µm thicknesses, mounted onto silan-
ized slides, and left to dry overnight at 37°C. Sections were
then deparaffinized and rehydrated. Antigen retrieval was
achieved by heat retrieval using a bench autoclave. Briefly,
slides were placed in Coplin jars containing enough 0.01 M
sodium citrate solution (pH 6.0) to cover the sections, then
autoclaved at 121°C for 10 minutes in the case of Her-2, and
15 minutes for both ER and PR. Slides were incubated with
100–200 µl of primary antibodies for 30 minutes at room tem-
perature in a moisture chamber, then rinsed in PBS. The dilu-
tion of the primary antibodies against ER and PR (Biogenex,
San Ramon, Ca, USA) was 1:130, and for Her-2/neu (Dako,
Carpintera, Ca, USA) 1:50. After washing, binding of antibod-
ies was detected by incubation for 10 minutes with bioti-
nylated goat anti-mouse antibody ready to use (LSAB2) from
Dako; the slides were then rinsed with PBS. Sections were
then incubated with streptavidin-horse radish peroxidase for
10 minutes. Finally, the sections were washed in 4 times in 4
minute changes of PBS, followed by adding 3,3 diaminoben-
zidine tetra hydrochloride (Biogenex) as a chromogen to pro-
duce the characteristic brown stain.
For each run of staining, a positive and negative control slide
were also prepared. The positive control slides were prepared
from breast carcinoma known to be positive for the antigen
under study. The negative control slides were prepared from
the same tissue block, but incubated with PBS instead of the
primary antibody.
A semi-quantitative histochemical score was used to record
results of ER and PR staining according to the system estab-
lished by Allred et al. [7]. This system considers both the pro-
portion and intensity of stained cells. The intensity score (IS)
ranges from 0 to 3, with 0 being no staining, 1 weak staining,
2 intermediate staining, and 3 intense staining. The proportion
score (PS) estimates the proportion of positive tumor cells and
ranges from 0 to 5, with 0 being non-reacting, 1 for 1% react-
ing tumor cells, 2 for 10% reacting tumor cells, 3 for one-third
reacting tumor cells, 4 for two-thirds reacting tumor cells, and
5 if 100% of tumor cells show reactivity. The PS and IS are
added to obtain a total score (TS) that ranges from 0 to 8.
Tumor cells with a total score of 3 to 8 were considered posi-
tive, whereas those with a TS less than 3 were considered
negative cases.
Her-2/neu was scored on a 0 to 3 scale according to the cri-
teria set by Dako. The staining was scored as: negative (0)
when no membrane staining was observed, or when membra-
nous staining was observed in less than 10% of the tumor
cells; weak positive (1+) if weak focal membrane staining was
seen in more than 10% of the tumor cells; intermediate (2+) if
weak to moderate, complete membrane staining was seen in
more than 10% of the tumor cells; and strongly positive (3+) if
intense membrane staining with weak to moderate cytoplas-
mic reactivity was seen in more than 10% of the tumor cells.
Figure 1 illustrates scores 1+, 2+, and 3+ as uses in this
study. In the final analysis, however, scores 0 and 1 were con-
sidered negative; score 2 was considered weakly positive; and
score 3 was considered strongly positive. Only score 3 cases
were considered as Her-2 overexpressing cases. Fluores-
cence in situ hybridization (FISH) was not performed on the
weak positive cases (score 2) in this study.
The Student's t-test was used for comparison of mean tumor
size and mean patient age for each category of cases. The chi
square test was used to compare the expression of ER, PR
and Her-2 among different cases, including: those above or
below 50 years of age; those with tumor size up to 2 cm with
those between 2 and 5 cm and those larger than 5 cm in size;
and those with up to 3 nodal metastases versus those with
more than 3 nodal metastases. The results were considered
statistically significant if the P value was < 0.05.Available online http://breast-cancer-research.com/content/7/5/R598
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Results
Of the 91 cases included in this study, infiltrating ductal carci-
noma (IDC) was the largest group, accounting for 84% (76/
91) of all the cases. This group included three mixed ductal
and lobular cases and two cases with associated Paget's dis-
ease. The second largest group, composed of seven cases,
was lobular carcinoma. The remaining cases included five
cases of mucinous carcinoma, one case of ductal carcinoma
in situ, one case of infiltrating ductal carcinoma with medullary
features, and one case of metaplastic carcinoma. Among the
infiltrating ductal carcinomas, there were only 3 grade 1 cases,
34 grade 2 cases, 37 grade 3 cases, and 2 cases were not
graded. The median age of all the cases was 47.5 years rang-
ing from 20 to 75 years. Fifty (57%) of 88 cases with known
age were below 50 years of age, whereas 38 cases were 50
years or older.
The mean age of patients with positive Her-2 expression was
42 years (Table 1), which is 10 years younger than those who
lack Her-2 expression. This difference is statistically significant
(P = 0.0007, Student's t-test). Similarly, Her-2 expression was
seen in 34% of patients less than 50 years of age as opposed
to 13% in patients 50 years or older (P = 0.003, chi square
test).
The mean age of patients with positive ER expression was
52.4 years as opposed to 43.7 among patients lacking ER
expression (P = 0.001, Student's t-test). For patients less than
50 years of age 42% were ER negative, whereas 68% of
patients 50 years or older were ER positive (P = 0.009, chi
square test).
The mean age for PR negative cases was 45.7 years and the
mean age for PR positive cases was 50.7 years (P = 0.06,
Student's t-test). PR positive patients comprised 48% of
patients less than 50 years of age compared to 58% of
patients 50 years old or older (P = 0.36, chi square test).
Tumors with strong Her-2 expression tended to be larger than
those lacking expression (scores 0 and 1), with mean sizes of
4.7 cm and 4 cm, respectively. Among patients with tumor size
more than 5 cm (T3), 35% were Her-2 positive (3+) compared
to 22% with tumors more than 2 and up to 5 cm in size (T2)
(P = 0.13, Chi square test).
The mean size of tumors expressing ER was 3.6 cm versus 5.3
cm for those lacking ER expression (P = 0.009, Student's t-
test). ER positive tumors comprised 57% of tumors between
2 and 5 cm but only 30% of those larger than 5 cm (P = 0.04,
chi square test).
For PR positive cases, the mean tumor size was 4.1 cm, and
the average size for PR negative cases was 4.8 cm. (P = 0.3,
Student's t-test). PR positive tumors comprised 57% of
Figure 1
Microscopy pictures illustrating the patterns of Her-2 immunostaining in  breast carcinoma Microscopy pictures illustrating the patterns of Her-2 immunostaining in 
breast carcinoma. (a) Weak positive (1+) pattern exemplified by weak 
focal membrane staining seen in more than 10% of the tumor cells. (b) 
Intermediate (2+) pattern, showing weak to moderate complete mem-
brane staining in more than 10% of the tumor cells. (c) Strongly posi-
tive (3+) pattern shows intense membrane staining with weak to 
moderate cytoplasmic reactivity in more than 10% of the tumor cells. 
Her-2 overexpressing cases comprised only those having strongly posi-
tive (3+) patterns of immunostaining.Breast Cancer Research    Vol 7 No 5    Almasri and Hamad 
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tumors between 2 and 5 cm compared to 35% of those larger
than 5 cm (P = 0.1, chi square test).
Lymph node status was known in 50 (55%) of the 91 cases
included in this study. As shown in Table 1, 56% of the Her-2
positive cases had more than three lymph node metastases, as
opposed to 42% among the Her-2 negative cases (P = 0.29,
chi square test).
The fraction of ER positive cases among those with up to three
lymph node metastases was 39%, slightly lower than the 48%
seen among those with more than three lymph node metas-
tases, but this difference was not statistically significant. Sim-
ilarly, no correlation between lymph node metastases and PR
expression was detected.
Grading analysis was limited to 74 of the 76 cases of IDC as
2 cases were not graded. Her-2 overexpression was seen in
similar proportions of grade 2 and 3 breast carcinomas,
26.4% and 27% of the cases, respectively. Similarly, no corre-
lation was detected between the grade of the tumors and
expression of ER and PR (P values 0.76 and 0.32,
respectively).
A negative correlation between Her-2 expression and ER and
PR was noted. Of the 22 Her-2 positive cases, 82% were ER
negative. On the other hand, 42% of ER negative carcinomas
were Her-2 positive. A negative correlation was also seen
between Her-2 and PR expression. Of the PR negative carci-
nomas, 68% were Her-2 positive, and 65% of Her-2 negative
cases were PR positive.
On the other hand, a positive correlation between ER and PR
was detected. Of the 48 ER positive cases, 36 (75%) were
PR positive. Similarly, 32 (74%) of the ER negative were also
PR negative.
We noticed that two distinct groups of carcinomas can be dis-
tinguished: group 1 includes those with negative Her-2 and
positive ER; and group 2 includes those with positive Her-2
and negative ER (Table 2). Group 1 had a relatively much
smaller tumor size (3.6 cm) and an older mean age of 55 years
at the time of diagnosis. Group 2 had an average tumor size of
4.9 cm and a mean age of 41 at the time of diagnosis. The dif-
ference between these groups was statistically highly
significant.
Discussion
Breast carcinoma is a disease with a tremendous heterogene-
ity in its clinical behavior. Clinical and pathological variables
such as tumor size, histologic grade, histologic type, lymph
node metastases, vascular space invasion, tumor cell prolifer-
ation, tumor necrosis, extent of ductal carcinoma in situ, age,
and pregnancy may help in predicting prognosis and the need
for adjuvant therapy [24]. Newer prognostic factors and pre-
dictors of response to therapy are needed, however, to distin-
guish subgroups with different biological features within
carcinomas that otherwise appear homogenous according to
Table 1
Her-2 status and estrogen and progesterone receptor expression in female breast carcinoma patients in Jordan
Her-2 weak positive Her-2 strong positive Her-2 negative ER positive ER negative PR positive PR negative
Mean age (years)a 43.7 42.3 53.2 52.40 43.68 50.74 45.71
No. of patients below 50 
years of age
15 17 18 21 29 24 26
No. of patients 50 years of 
age or older
5 5 28 26 12 22 16
Mean size (cm)b 4.9 4.72 4.02 3.57 5.3 4.06 4.79
No. of T1(up to 2 cm) 
tumors
4 4 7 9687
No. of T2 (more than 2 and 
up to 5 cm) tumors
11 11 29 29 22 29 22
No. of T3 (more than 5 cm) 
tumors
6 7 7 61 471 3
No lymph node 
metastasesc
1 3 3 2534
1–3 lymph node 
metastases
358 7 9 1 0 6
More than 3 lymph node 
metastases
9 10 8 13 14 13 14
aAge was unknown for three cases; bsize was unknown for five cases;
cdetermination of axillary lymph node status was limited to 50 patients who underwent lymph node dissection.Available online http://breast-cancer-research.com/content/7/5/R598
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classic pathological and clinical criteria. ER, PR and Her-2 rep-
resent the most acceptable factors for predicting prognosis,
response or resistance to treatment, and the potential use of
newer drugs such as trastuzumab in the case of Her-2
overexpression.
In this study, we found that 22 (24%) of 91 cases were Her-2
positive. Although there is a wide variation in Her-2 overex-
pression and amplification, our figure appears to be within the
commonly accepted rate of 20% to 30% [9,11-13,26,27]. It
does appear, however, to be lower than those reported in East
Asia [28,29] and in neighboring countries such as Lebanon
[30] and Egypt [31]. Her-2 was expressed in 28% of the infil-
trating ductal carcinoma cases compared to only 14% of our
seven lobular carcinoma cases. T h i s  p a t t e r n  o f  l o w  H e r - 2
expression in lobular carcinoma is in agreement with data
reported in the literature [32-35]. None of the other types of
breast carcinoma showed evidence of Her-2 expression.
We found a clear negative correlation between Her-2 overex-
pression and age in this study. The mean age of Her-2 positive
patients was 11 years less than those patients lacking Her-2
expression, a statistically significant difference. Similarly,
patients younger than 50 years of age were 2.6 times more
likely to overexpress Her-2 than patients 50 years of age or
older (34% versus 13%). It should be pointed out that higher
rates of Her-2 overexpression in young patients have been
documented in previous studies [31,36,37]. Our results show
a tendency of Her-2 overexpression to be more associated
with larger tumor size. Tumors expressing Her-2 were on the
average 0.7 cm larger than those lacking Her-2 expression,
although this difference was not statistically significant. Simi-
larly, the fraction of tumors larger than 5 cm tended to have
higher rates of Her-2 expression than those 2 to 5 cm in size
(35% versus 22%), but this difference was not statistically sig-
nificant (P = 0.13).
Other groups have shown a direct relationship between lymph
node metastases and Her-2 expression [32,38-40]. Our data
reveal that 56% of Her-2 overexpressing tumors had more
than three lymph node metastases, as opposed to 42% of
Her-2 negative cases, although this difference was not statis-
tically significant. We believe that the low number of cases
with known nodal status is responsible for the lack of signifi-
cant correlation in this study; therefore, future studies with
larger numbers of patients are needed to confirm the associa-
tion of Her-2 expression with nodal metastases. Similarly, we
were unable to show a significant relationship between Her-2
expression and the histologic grade of breast carcinoma.
Other studies concluded that Her-2 expression or amplifica-
t i o n  i s  a s s o c i a t e d  w i t h  g r a d e  [ 3 2 , 3 6 , 4 0 , 4 1 ] .  I t  s h o u l d  b e
pointed out, however, that the low number of grade 1 carcino-
mas (three cases) in this study would not allow us to evaluate
this variable with any degree of confidence.
ER was expressed in 53% of our cases. This figure is less than
the number of ER positive cases reported in the literature
(60% to 70%) [7]; however, there is a wide variation in ER
expression and our figure would probably fall in the lower
reported ranges [42-46]. In our study, there is a strong
correlation between patient age and ER expression. The mean
age for ER expressing carcinoma patients was nine years
older than those lacking ER expression (P = 0.001). Similarly,
68% of patients 50 years or older were ER positive as
opposed to 42% of patients less than 50 years old; this differ-
ence was statistically significant (P = 0.01). These findings are
in agreement with other reports in the literature, which show
an association between ER expression in breast carcinoma
patients and age at the time of diagnosis [42,47,48]. In our
cases, we also found that ER expressing breast carcinomas
were, on average, 1.6 cm smaller than carcinomas lacking ER
expression (P = 0.009). Similarly, 57% of T2 tumors (2 to 5
cm) were ER positive as opposed to only 30% of T3 tumors
(P = 0.04). These figures are also in agreement with data
Table 2
Her-2 negative and ER positive compared to Her-2 positive and ER negative breast carcinoma cases
Her-2 negative and ER positive Her-2 positive and ER negative P value
No. of patients 35 18 -
Mean age (years) 54.88 41.2 0.0003
Mean tumor size (cm) 3.6 4.9 0.088
No. of patients without axillary node 
dissection
21 8 0.002
No. of patients who underwent axillary 
nodes dissection
14 23
No. of patients with up to 3 lymph node 
metastases
81 1 0 . 4 8
No. of patients with more than 3 lymph 
node metastases
61 2Breast Cancer Research    Vol 7 No 5    Almasri and Hamad 
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reported in the literature [38,43,49]. Our data also show a
strong inverse correlation between Her-2 and ER expression,
which is in agreement with data reported by others
[10,39,50,51]. Unlike reported data that shows a correlation
between ER expression and tumor grade [41,43,47,49], how-
ever, we were unable to confirm such a correlation in our
cases. The lack of association between ER expression and
lymph node status in our study supports the findings of Char-
iyalertsak et al. [50] who found no correlation between ER
expression and lymph node status in their breast carcinomas
cases.
A strong correlation between ER and PR expression was
noted in our series. Unlike ER, however, there was only a low
tendency for PR to be associated with smaller carcinomas and
with older patients, but this tendency was not statistically
significant.
Conclusion
We have shown for the first time that Her-2 is expressed in
approximately one-fourth of breast carcinomas in Jordan. This
expression is strongly associated with some known bad path-
ological and clinical prognostic factors, such as young age,
large tumor size and lack of ER and PR expression. In contrast,
ER expression was seen in older patients, and was associated
with small tumor size and lack of Her-2 expression. One-fifth of
the breast carcinoma cases in this study have a profile charac-
terized by overexpression of Her-2 and lack of ER expression.
This subgroup of patients appears to represent an aggressive
form of breast carcinoma characterized by young age presen-
tation (median 40 years), large tumor size (5.4 cm), and high
rates of axillary lymph node metastases (four or more).
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